Highest-materiality recent filing
Agape ATP regains Nasdaq minimum bid price compliance; delisting hearing cancelled
Received Nasdaq notice on Mar 10, 2026, that bid price compliance restored under Rule 5550(a)(2).
Agape ATP subsidiary signs non-exclusive oil & gas trading pact with Citadel Investment LLC
ATPC Green Energy, a wholly owned subsidiary, entered a non-exclusive collaboration with Dubai-based Citadel Investment LLC for oil, gas, and petrochemical trading.
Agape ATP announces 1-for-50 reverse stock split effective Feb 9, 2026
Reverse split ratio of 1-for-50; effective February 9, 2026; split-adjusted trading begins February 10, 2026 on Nasdaq.
Agape ATP receives Nasdaq delisting notice for low stock price; plans to appeal
Received delisting notice on Feb 2, 2026 under Low Priced Stocks rule (bid ≤ $0.10 for 10 days).
Agape ATP shareholders approve 60x increase in authorized shares and reverse split up to 1:5000
Authorized shares increased from 500M to 30B; approved with 30,073,422 for, 22,106 against.
Received Nasdaq notice Jan 27, 2026 for failing $1.00 minimum bid price based on closing bid Dec 10, 2025–Jan 26, 2026.
Agape ATP issues statement on stock volatility; no material undisclosed developments
Press release addresses recent volatility in ATPC share price, states business operations continue as usual.
Deputy Chairman and Executive Director John Hing Vong resigns effective Nov 24, 2025
John Hing Vong resigned as Deputy Chairman and Executive Director, effective November 24, 2025.
Agape ATP enters strategic partnership with GSS and BMT for energy and infrastructure projects
Partnership with GSS and BMT targets petroleum trade, energy transition, and infrastructure across SEA, Africa, and Eastern Europe.
Agape ATP signs $24B supply agreements for jet fuel and diesel with Swiss One Oil & Gas
Aggregate SPA value approx $24B for 12-month supply of Jet Fuel A1 and EN590 diesel to Swiss One Oil & Gas AG.
Agape ATP closes $23M Reg S private placement; issues 46M shares at $0.50
Closed $23M private placement via issuance of 46M shares at $0.50/share to non-U.S. investors on March 24, 2025.
Agape ATP raises $23M private placement; 46M shares at $0.50, shares to increase 12.5x
Sold 46M shares at $0.50 each to 18 non-U.S. institutional investors under Regulation S for $23M.
Agape ATP Corp. announces strategic partnership for oil & gas sales and purchase operations
Press release issued February 24, 2025, announcing a strategic partnership to enhance oil and gas sales and purchase operations.
Agape ATP shareholders approve 10x authorized share increase and up to 46M share issuance
Shareholders approved increasing authorized common shares from 50M to 500M (1,606,668 for, 41,742 against).
Agape ATP signs three MOUs with Indonesian hospitals for clinical studies on health products
Signed MOUs with Dr. Sardjito General Hospital, Dr. H.A. Rotinsulu Lung Hospital, and Dr. M. Goenawan Partowidigdo Respiratory Hospital in Indonesia.
Dr. Vong John Hing resigned as independent director and committee roles effective Nov 15, 2024; remains as Deputy Chairman.
ATPC issues business pillar update without material financial details
Press release outlines six divisions: wellness, anti-aging, green energy, therapy, medical device, senior living.
Agape ATP Corporation announces director resignation and appointment effective October 1, 2024
Chee Chin Aik resigned as independent director and chair of nominating and governance committee on October 1, 2024.
Agape ATP partners with Formedic to launch LEGA respiratory care device
Collaboration agreement signed Sept 25, 2024, to introduce LEGA, an electronic chest percussion device for airway clearance.
Agape ATP regains Nasdaq minimum bid price compliance after 10 consecutive days above $1.00
Received Nasdaq notice on Sept 17, 2024 confirming compliance with $1 minimum bid price rule.
Collaboration agreement signed Aug 31, 2024; press release issued Sept 13, 2024.
Agape ATP implements 1-for-20 reverse stock split, cuts authorized shares to 50M
Reverse stock split 1-for-20 effective August 30, 2024; authorized shares reduced from 1B to 50M.
Agape ATP announces 1-for-20 reverse stock split effective Aug 30, authorized shares reduced to 50M
Reverse stock split at 1:20 ratio effective August 30, 2024; trading begins split-adjusted that day.
ATPC Green Energy partners with Phoenix Green Energy to develop thin-film solar panels in Malaysia
ATPC subsidiary ATPC Green Energy signed a collaboration agreement with Phoenix Green Energy Sdn. Bhd. on Aug 19, 2024.
Agape ATP enters elderly care and pain management collaborations with Sweet Home and Cedar Wellness
Collaboration with Sweet Home to provide elderly care services; plans to expand to 10 facilities by first half of 2026.
Agape ATP fails to regain bid price compliance; Nasdaq delisting scheduled for July 30; will appeal
Received Nasdaq notice on July 19, 2024, for failing to regain minimum $1 bid price after 180-day period.
Agape ATP stockholders re-elect all five directors at 2024 annual meeting
All five director nominees re-elected with over 96% of votes cast; How Kok Choong received 99.68%.
Agape ATP subsidiary ATPC Green Energy collaborates with B&H; B&H management gets 30% stake
ATPC Green Energy (wholly owned) signs Collaboration Agreement with B&H Intec Solution Sdn. Bhd.
Agape ATP dismisses Marcum Asia as auditor, hires Assentsure PAC
Board dismissed Marcum Asia CPAs LLP effective April 25, 2024; no disagreements on accounting principles or practices.
Agape ATP regains Nasdaq compliance on minimum equity rule after deficiency notice
Received March 28 deficiency letter for failing MVLS of $35M under Rule 5550(b)(2).
Agape ATP receives Nasdaq MVLS deficiency notice; 180 days to regain compliance
Nasdaq notified Agape ATP on March 28, 2024 that MVLS fell below $35M minimum from Feb 14 to Mar 27, 2024.
Agape ATP receives Nasdaq bid price deficiency notice; faces potential delisting
Nasdaq notified Agape ATP on Jan 18, 2024, that its bid price closed below $1 for 30 consecutive trading days.
CEO Dr. How Kok Choong's salary amended from $0 to $400,000 per annum
Compensation amendment for CEO Dr. How Kok Choong approved December 28, 2023.
Agape ATP elects Dr. Wilfrendo Fernando Cortizo as director effective Nov 21, 2023
Dr. Cortizo elected to the Board on November 21, 2023; no committee assignments yet.
Agape ATP authorizes up to $1M share repurchase over 6 months
Board authorized repurchase of up to $1M of common stock over the next 6 months.
Agape ATP signs MOAs to acquire 51% of Volt Industries, form renewable energy SPV
Intends to acquire 51% stake in Volt Industries, a developer of EV charging stations in Pahang.
Agape ATP closes IPO of 1.65M shares at $4.00; warrants for 115,500 shares
Closed IPO of 1,650,000 common shares at $4.00 per share on October 13, 2023.
Executive director Mohd Shaharuddin Bin Abdullah resigns; Tjong Budisantoso, Phd appointed
Mohd Shaharuddin Bin Abdullah resigned as executive director in March 2023; employment terminated immediately.
Agape ATP dismisses Friedman LLP, engages Marcum Asia CPAs as new auditor
Friedman LLP combined with Marcum LLP effective September 1, 2022.
Agape ATP amends 8-K to correct name of appointed independent director
Mr. Ramesh Ruben Louis, Phd appointed as independent director effective upon NASDAQ/NYSE IPO.
Agape ATP corrects share forfeiture date; 215M shares cancelled in Feb 2022
CEO How Kok Choong forfeited 215,008,035 shares of common stock pursuant to agreement dated January 20, 2022.
Agape ATP amends 8-K to correct share forfeiture cancellation date to Dec 30, 2021
Corrected cancellation date for total 85,992,000 forfeited shares to December 30, 2021.
Agape ATP appoints Ramesh Rubin Louis as independent director, effective upon IPO closing
Mr. Louis, PhD, appointed as independent director on March 30, 2022, contingent on closing of IPO on NASDAQ/NYSE.
Agape ATP CEO forfeits 215M shares, reducing outstanding count
How Kok Choong forfeited 215,008,035 shares to the company on Feb. 28, 2022.
Agape ATP cancels 86.99M shares via forfeiture agreements with HKC Talent and other shareholders
HKC Talent Limited forfeited 41,750,000 shares of common stock.
On November 15, 2024, Ms. Rose Marie Kadende Kaiser, PhD (“Ms. Rose, PhD) was appointed as an independent director of the Board to fill the vacancy left by Dr Vong, PhD’s resignation.
Dr. Vong, PhD will serve as the Deputy Chairman of the Board following his resignation effective on the same day.
On October 1, 2024, Mr. Chee Chin Aik (“Mr. Chee”) resigned as our independent director of the Board of Directors (the “Board”), the chairman of the nominating and governance committee and as a member of the audit and compensation committees of the Agape ATP Corporation (the “Company”), effective from October 1, 2024.
On October 1, 2024, Dr. Ni Luh Dharma Kerti Natih (Dr. Natih) was appointed as an independent director of the Board to fill the vacancy left by Mr. Chee’s resignation.
elected Dr. Wilfrendo Fernando Cortizo, Phd (Dr. Cortizo) as a director of the Board.
Mr. Mohd Shaharuddin Bin Abdullah resigned from the Company as an executive director and his employment agreement terminated with immediate effect.
Mr. Tjong Budisantoso, Phd ("Mr. Budisantoso, Phd") was appointed as an executive director to fill the vacancy, effective on the listing of our stock on Nasdaq Capital Market.
On March 30, 2022, Mr. Ramesh Ruben Louis, Phd (“Mr. Louis, Phd”) was appointed as an independent director of the board of directors (the “Board”) of Agape ATP Corporation (the “Company”), effective upon the Company’s initial public offering on the NASDAQ Stock Market/The New York Stock Exchange.
On March 30, 2022, Mr. Ramesh Rubin Louis, Phd (“Mr. Louis, Phd”) was appointed as an independent director of the board of directors (the “Board”) of Agape ATP Corporation (the “Company”), effective upon the Company’s initial public offering on the NASDAQ Stock Market/The New York Stock Exchange.
Max materiality 0.90 · Median 0.55 · Most common event other_material